News - Abzena

Filter by year

Filter by topic

Funding update: Seeking to monetise royalty-bearing ABZENA Inside products

Cambridge, UK, 14 June 2018 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Company’, and together with its subsidiaries, the ‘Group’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, provides an update on its fundraising activities. At the time of the recent full-year results announcement on 4 […] Read more

Full year results: a year of transition – revenue growth driven by investment programme

Cambridge, UK, 4 June 2018 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, has published its full year results for the year to 31 March 2018. Corporate summary FY18 was a year of transition; ambitious growth targets set […] Read more

Notice of full year results

Cambridge, UK, 29 May 2018 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, will publish its full-year results for the year to 31 March 2018 on Monday, 4 June 2018. A presentation for analysts will be held at 09:30 […] Read more

Abzena hosts first Biopharmaceutical Discovery and Development Symposium and open day at Cambridge, UK site

Cambridge, UK, 26 April 2018 – Abzena plc (AIM: ABZA, ‘Abzena’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, is today hosting its first Biopharmaceutical Discovery and Development Symposium and open day, showcasing its new facility at the Babraham Research Campus in Cambridge, UK. The Symposium […] Read more

Pre-Close Period Trading Update FY2018

Cambridge, UK, 16 April 2018 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, today announces its unaudited pre-close update for the year ended 31 March 2018 (‘FY2018’). Following a stronger second half to the year, the Group expects to […] Read more

Facility Remodelling Completed for Abzena’s New Antibody-Drug Conjugate GMP Manufacturing Suite

CAMBRIDGE, England & BRISTOL, PA, USA, Abzena plc, the life sciences group providing services and technologies to enable the design, development and manufacture of biopharmaceutical products, has announced the completion of the facility remodelling for its new antibody-drug conjugate (ADC) GMP manufacturing suite at its Bristol, Pennsylvania site. The facility is being equipped with state-of-the-art […] Read more

Abzena strengthens specialized bioassay offering through access agreement with major cell line depository

Cambridge, UK, 13 March 2018 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), the life sciences group providing services and technologies to enable the discovery, design, development and manufacture of biopharmaceutical products, has signed an agreement to access a major cell line depository. The agreement with an unnamed institution will allow Abzena access to […] Read more

Abzena takes on new facilities in Cambridge, UK and San Diego

Cambridge, UK 5 January 2018 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, provides an update on its UK and US facilities. In Cambridge, UK, the Group’s lease has commenced for 30,000 square feet of space in […] Read more

Babraham Bioscience Technologies “Technology Development Laboratory” (TDL) moves to Abzena

Cambridge, UK, 5 January 2018 – Abzena plc (AIM: ABZA, ‘Abzena’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has entered into an agreement with Babraham Bioscience Technologies Limited (BBT), the company that manages and develops the Babraham Research Campus, to run and develop the services formerly […] Read more

Abzena selects Sartorius Stedim Biotech to equip their U.S. based development and manufacturing sites in San Diego and Bristol

Goettingen, Germany, January 4, 2018 – Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as their preferred equipment supplier in the U.S. Abzena has selected Sartorius Stedim to equip their integrated CDMO facilities in Bristol, PA, for the development […] Read more

Interested in our services? Get In Touch